Breaking News Instant updates and real-time market news.

AMRN

Amarin

$4.19

(0.00%)

16:34
01/04/18
01/04
16:34
01/04/18
16:34

Amarin sees Q4 revenue $51M-$54M, consensus $49.6M

Q4 net revenue growth was driven by increased prescriptions for Vascepa capsules. Wholesaler inventory levels of Vascepa were within normal industry ranges at the end of 2017.

AMRN Amarin
$4.19

(0.00%)

08/03/17
HCWC
08/03/17
NO CHANGE
Target $10
HCWC
Buy
Amarin valuation attractive into interim data, says H.C. Wainwright
Amarin's current valuation is supported by the "strong" underlying Vascepa sales alone, H.C. Wainwright analyst Andrew Fein tells investors in a post-earnings research note. He believes the recent share pullback provides an opportunity for a "free shot" at the upcoming interim look of the REDUCE-IT trial. Investors are ascribing no value to the interim nor full study at all, the analyst contends. He reiterates a Buy rating on Amarin with a $10 price target.
08/29/17
CANT
08/29/17
NO CHANGE
Target $10
CANT
Overweight
Cantor positive on Amarin after Novartis study results
Cantor Fitzgerald analyst Louise Chen believes the Phase 3 CANTOS study results from Novartis (NVS) support the hypothesis that a long-term drug treatment focused on an anti-inflammatory mechanism in patients with a prior heart attack and inflammatory atherosclerosis can reduce cardiovascular events. In two Phase 3 trials, Amarin's (AMRN) Vascepa affected inflammatory markers including hsCRP and Lp-PLA2 while also improving lipid biomarkers, Chen tells investors in a research note. CANTOS and other recently reported studies help to increase her confidence in a positive and commercial outcome for Amarin's REDUCE-IT trial. The analyst has an Overweight rating on the shares with a $10 price target.
12/14/17
CANT
12/14/17
NO CHANGE
Target $10
CANT
Overweight
Cantor sees Vascepa benefits driving Amarin shares higher
Research recently presented to the American Heart Association by a key opinion leader showed over-the-counter fish oil supplements may contain mercury, are high in saturated fats and sugar, and may even raise lipid levels and deplete antioxidants, Cantor Fitzgerald analyst Louise Chen wrote yesterday in a research note titled "Something Smelly about Unregulated Fish Oil Contaminants." FDA approved products, such as Amarin's Vascepa, were found to be pure and safe, Chen adds. The research reinforced her view that the "differentiation and scientific benefit" of Vascepa will drive shares of Amarin higher. The analyst kept an Overweight rating on Amarin shares with a $10 price target.
12/20/17
CANT
12/20/17
NO CHANGE
Target $10
CANT
Overweight
Cantor more confident in $10 target for Amarin after management meetings
Cantor Fitzgerald analyst Louise Chen says that after spending two days with management, she has increased confidence in her Overweight rating and $10 price target for Amarin shares. The analyst believes the company's Vascepa can help lower deaths and the cost of care for patients with high triglycerides levels without increasing LDL-C. Chen believes this is still underappreciated in Amarin shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.